CVMP opinions on veterinary medicinal products

Under Regulation (EC) No 726/2004, the Committee adopted by consensus a positive opinion for a marketing authorisation application for Oxmax (hemoglobin betafumaril (bovine)), from New Alpha Innovation Biopharmaceutical Ireland Limited, a new product as an adjunct therapy in the management of haemorrhagic shock in dogs.

Under Regulation (EU) 2019/6, the Committee adopted by consensus a positive opinion for a marketing authorisation application for Loxitab (meloxicam), from CP-Pharma Handelsgesellschaft mbH, a new generic product for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

The Committee adopted by consensus a positive opinion for a marketing authorisation for Poulvac Procerta HVT-IBD, from Zoetis Belgium, a new vaccine for the active immunisation of one-day-old chickens and 18-19 day-old embryonated chicken eggs to reduce mortality, clinical signs and lesions caused by…